466 related articles for article (PubMed ID: 10448105)
1. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors.
Melck D; Bisogno T; De Petrocellis L; Chuang H; Julius D; Bifulco M; Di Marzo V
Biochem Biophys Res Commun; 1999 Aug; 262(1):275-84. PubMed ID: 10448105
[TBL] [Abstract][Full Text] [Related]
2. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid.
Di Marzo V; Griffin G; De Petrocellis L; Brandi I; Bisogno T; Williams W; Grier MC; Kulasegram S; Mahadevan A; Razdan RK; Martin BR
J Pharmacol Exp Ther; 2002 Mar; 300(3):984-91. PubMed ID: 11861807
[TBL] [Abstract][Full Text] [Related]
3. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
Bisogno T; Hanus L; De Petrocellis L; Tchilibon S; Ponde DE; Brandi I; Moriello AS; Davis JB; Mechoulam R; Di Marzo V
Br J Pharmacol; 2001 Oct; 134(4):845-52. PubMed ID: 11606325
[TBL] [Abstract][Full Text] [Related]
4. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues.
Di Marzo V; Lastres-Becker I; Bisogno T; De Petrocellis L; Milone A; Davis JB; Fernandez-Ruiz JJ
Eur J Pharmacol; 2001 May; 420(2-3):123-31. PubMed ID: 11408034
[TBL] [Abstract][Full Text] [Related]
5. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands.
Di Marzo V; Bisogno T; De Petrocellis L; Brandi I; Jefferson RG; Winckler RL; Davis JB; Dasse O; Mahadevan A; Razdan RK; Martin BR
Biochem Biophys Res Commun; 2001 Feb; 281(2):444-51. PubMed ID: 11181068
[TBL] [Abstract][Full Text] [Related]
6. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity.
De Petrocellis L; Bisogno T; Davis JB; Pertwee RG; Di Marzo V
FEBS Lett; 2000 Oct; 483(1):52-6. PubMed ID: 11033355
[TBL] [Abstract][Full Text] [Related]
7. Interactions between synthetic vanilloids and the endogenous cannabinoid system.
Di Marzo V; Bisogno T; Melck D; Ross R; Brockie H; Stevenson L; Pertwee R; De Petrocellis L
FEBS Lett; 1998 Oct; 436(3):449-54. PubMed ID: 9801167
[TBL] [Abstract][Full Text] [Related]
8. Anandamide transport inhibition by the vanilloid agonist olvanil.
Beltramo M; Piomelli D
Eur J Pharmacol; 1999 Jan; 364(1):75-8. PubMed ID: 9920187
[TBL] [Abstract][Full Text] [Related]
9. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide.
Zygmunt PM; Petersson J; Andersson DA; Chuang H; Sørgård M; Di Marzo V; Julius D; Högestätt ED
Nature; 1999 Jul; 400(6743):452-7. PubMed ID: 10440374
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.
Deutsch DG; Lin S; Hill WA; Morse KL; Salehani D; Arreaza G; Omeir RL; Makriyannis A
Biochem Biophys Res Commun; 1997 Feb; 231(1):217-21. PubMed ID: 9070252
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.
Ross RA; Gibson TM; Brockie HC; Leslie M; Pashmi G; Craib SJ; Di Marzo V; Pertwee RG
Br J Pharmacol; 2001 Feb; 132(3):631-40. PubMed ID: 11159715
[TBL] [Abstract][Full Text] [Related]
12. Novel selective and metabolically stable inhibitors of anandamide cellular uptake.
Ortar G; Ligresti A; De Petrocellis L; Morera E; Di Marzo V
Biochem Pharmacol; 2003 May; 65(9):1473-81. PubMed ID: 12732359
[TBL] [Abstract][Full Text] [Related]
13. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo.
Bisogno T; Melck D; Bobrov MYu ; Gretskaya NM; Bezuglov VV; De Petrocellis L; Di Marzo V
Biochem J; 2000 Nov; 351 Pt 3(Pt 3):817-24. PubMed ID: 11042139
[TBL] [Abstract][Full Text] [Related]
14. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases.
Veldhuis WB; van der Stelt M; Wadman MW; van Zadelhoff G; Maccarrone M; Fezza F; Veldink GA; Vliegenthart JF; Bär PR; Nicolay K; Di Marzo V
J Neurosci; 2003 May; 23(10):4127-33. PubMed ID: 12764100
[TBL] [Abstract][Full Text] [Related]
16. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide.
Jonsson KO; Vandevoorde S; Lambert DM; Tiger G; Fowler CJ
Br J Pharmacol; 2001 Aug; 133(8):1263-75. PubMed ID: 11498512
[TBL] [Abstract][Full Text] [Related]
17. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
[TBL] [Abstract][Full Text] [Related]
18. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
[TBL] [Abstract][Full Text] [Related]
19. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide.
Di Marzo V; Breivogel C; Bisogno T; Melck D; Patrick G; Tao Q; Szallasi A; Razdan RK; Martin BR
Eur J Pharmacol; 2000 Oct; 406(3):363-74. PubMed ID: 11040343
[TBL] [Abstract][Full Text] [Related]
20. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
